- The results showed nearly 50% reduction in lung injury in the C21 group compared the
placebo group - These positive findings together with previous clinical results1 suggest that C21 could accelerate recovery
- C21 is currently being evaluated in a phase 3 trial in COVID-19 patients
The new results are based on high-resolution computerized tomography (HRCT) scans from a 3-6-month non-interventional, retrospective follow-up trial, ATTRACT-22. This study included a subset of 33 patients with COVID-19 participating in Vicore's phase 2 ATTRACT trial3. The C21-treated patients (n=17) displayed reduced pathological abnormalities compared to the placebo-treated group (n=16); in the C21 group, on average 10.3% of the lung was affected compared to 19.2% in the placebo group. The dominating radiological change was ground glass opacity, a pathological characteristic following viral respiratory infection. Although functional tests were not performed in this study, it is known that reduced gas exchange is a common lung function abnormality in COVID-19 patients with an abnormal HRCT at three months.
"These promising results are encouraging news for patients and physicians involved in Vicore's ongoing phase 3 ATTRACT-34 trial in COVID-19 and suggests that C21 have the potential to accelerate recovery after COVID-19. It also indicates that the lasting injury that some patients experience after severe COVID-19 may be improved by treatment with C21." said
Lung injury scores were assessed by an independent blinded radiologist experienced in HRCT scan reading at a national center for thoracic disease in the
The results of the ATTRACT trial were recently published in EClinicalMedicine, a peer reviewed clinical journal published by
ATTRACT-3, ongoing phase 3-trial in COVID-19
The pivotal phase 3 ATTRACT-3 trial design was approved by the FDA in
C21 - a first-in-class AT2R agonist
C21 is a first-in-class, orally available, low molecular weight, angiotensin II type 2 receptor (AT2R) agonist that activates the "protective arm" of the renin-angiotensin system (RAS) leading to resolution and regeneration following tissue damage. The compound is currently in a phase 2 proof-of-concept trial in IPF5, and in a pivotal phase 3 trial in COVID-19.
The ATTRACT study received
For further information, please contact:
Phone: +46 70 975 98 63
E-mail: carl-johan.dalsgaard@vicorepharma.com
This information is such that
1. Phase 2 data from COVID-19 trial (ATTRACT)
2. NCT04878913
3. NCT04452435
4. NCT04880642
5. NCT04533022
https://news.cision.com/vicore-pharma-holding-ab/r/vicore-s-c21-reduces-long-term-lung-injury-after-covid-19-in-the-attract-phase-2-extension-study,c3445191
https://mb.cision.com/Main/15668/3445191/1490003.pdf
(c) 2021 Cision. All rights reserved., source